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Background
Lung cancer is the leading cause of cancer death world-
wide. Non-small cell lung cancer (NSCLC) accounts for
the majority of lung cancer. The incidence and prognosis
in NSCLC demonstrates gender difference [1,2]; therefore,
sex steroids and/or their receptors may play important
roles during lung tumorigenesis and cancer progression.
In our previous investigation, cell proliferation, migration,
invasion, and tumor formation were inhibited by shRNA
interference of androgen receptor (AR) in non-small cell
lung cancer (NSCLC) cells lines. The expressions of cyclin
D1 also decreased to less than 50% after AR knockdown.
However, the roles of androgen receptor in treatment of
NSCLC are still controversial.
Materials and methods
To validate therapeutic effects of targeting androgen
receptor on NSCLC, initially we administered 8 doses of
tobacco carcinogens, 4-(methylnitrosamino)-1-(3-pyri-
dyl)-1-butanone (NNK) and benzo[a]pyrene (BaP), to
induce lung tumor growth in female A/JB6.129-Arlox Tg
(Mx1-cre)1Cgn mice when they were 5 weeks old. In the
next step, targeted Ar gene disruption was induced with
6 doses of polyinosinic: polycytidylic acid (polyI:C) intra-
peritoneal injection in Mx1-cre+ mice when they were 26
weeks old. We also performed 6 doses of normal saline
injection to NNK+BaP-treated female A/JB6.129-Arlox
Tg(Mx1-cre)1Cgn mice in the same time point for
the control group. Finally, all mice were sacrificed in
31 weeks old and total lung nodules and tumor larger
than 1 mm in diameter were calculated under dissection
microscope.
Results
In immunohistochemical studies, AR expression in lung
was deficient in Mx1-cre+ mice after polyI:C treatment.
Pulmonary expression of cyclin D1 was also suppressed in
polyI:C treated Mx1-cre+ mice. The number of total
nodules in bilateral lungs from polyI:C treated Mx1-cre+
mice (n=8) was 7.375 ± 5.476 (mean ± S.E.). In compari-
son, the total number of lung nodules from normal saline
treated Mx1-cre+ mice (n=8) was 14.375 ± 7.269 (p=
0.0456, 95% CIs on the mean = 9.235 to 19.515). The
number of large nodules (>1 mm in diameter) in bilateral
lungs was 1.375 ± 1.188 in polyI:C treated Mx1-cre+ mice
and 6.25 ± 4.464 in normal saline treated Mx1-cre+ con-
trol mice (p= 0.00492, 95% CIs on the mean = 3.093 to
9.407). Deficient AR expression through inducible disrup-
tion of Ar gene could reduce lung tumor multiplicity and
further inhibit tumor progression (decrease tumor
volume) in tobacco carcinogens-induced lung tumorigen-
esis model.
Conclusions
Our data indicate that androgen receptor warrants con-
sideration as a novel therapeutic target for NSCLC in a
clinical lung cancer treatment trial.
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